FDA Approves First Influenza Vaccine for Self-Administration
The nasal spray flu vaccine is available for self- or caregiver-administration by prescription for individuals aged 2 to 49.
Tag: nasal spray
All
Latest
FDA Approves First Influenza Vaccine for Self-Administration
The nasal spray flu vaccine is available for self- or caregiver-administration by prescription for individuals aged 2 to 49.
Read More
FDA Issues Warning for SnoreStop Nasal Spray Amid Safety Concerns
The FDA says it has repeatedly called for a recall of SnoreStop Nasal Spray due to contamination risks, but the manufacturer has not complied to date.
Read More
FDA Approves First Epinephrine Nasal Spray for Anaphylaxis
The epinephrine nasal spray provides a needle-free option for rapid emergency treatment of severe allergic reactions.
Read More
NIH Begins Trial of Experimental Nasal COVID-19 Vaccine
The phase 1 clinical trial to test the safety and immune response of an experimental nasal spray vaccine designed to provide broader protection against emerging COVID-19 variants.
Read More
Live Vaccines Can Be Given With Dupilumab, ACAAI Advises
A new ACAAI position paper concludes that live vaccines are generally safe for patients on dupilumab but emphasizes the importance of shared decision-making.
Read More
Investigational Nasal Spray Modestly Reduces OSA Severity
Researchers have discovered that a bedtime nasal spray has the potential to reduce the severity of OSA and next-day blood pressure.
Read More
Neffy Epinephrine Nasal Spray Proves Effective in Anaphylaxis
ARS Pharmaceuticals plans to resubmit its NDA for Neffy following successful clinical trials, with hopes of gaining approval later in the year.
Read More
FDA to Review FluMist Nasal Spray Influenza Vaccine
A supplemental biologics application for AstraZeneca’s FluMist Quadrivalent is currently being reviewed by the FDA. If approved, FluMist would be the first needle-free, nasal spray influenza vaccine available to be self-administered by patients or caregivers.
Read More
FDA Greenlights Prescription Nasal Spray to Reverse Opioid Overdose
The nalmefene hydrochloride nasal spray is indicated for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older.
Read MoreFDA Approves Amphastar’s Naloxone Nasal Spray
The FDA approved Amphastar Pharma’s naloxone hydrochloride nasal spray (4mg) for the emergency treatment of known or suspected opioid overdose.
Read More
AAHI Awarded $9.9M to Develop Nasal Spray Influenza Vaccine
The 40-month project may culminate in a prototype bivalent vaccine candidate that is effective against both the H5N1 and H7N9 strains of influenza, according to Access to Advanced Health Institute.
Read More
COPD Patients Open to Antiviral Nasal Spray to Reduce Seasonal Flare-Ups
A survey found individuals with COPD were overwhelmingly positive about the prospect of taking an antiviral nasal spray throughout the winter season to prevent COPD flare-ups.
Read More
Green Pharmaceuticals Recalls SnoreStop NasoSpray Lot
Green Pharmaceuticals Inc is voluntarily recalling lot 2373/21222 of SnoreStop NasoSpray.
Read More
COVID Nasal Spray May Inhibit Infection
Researchers are developing a COVID nasal spray to inhibit SARS-CoV-2 infection. The newly discovered small molecule N-0385 could be sprayed into people’s noses to prevent COVID-19 illness.
Read More
Antiviral Nasal Spray Being Developed by ENA Respiratory, COPD Foundation
ENA Respiratory and the COPD Foundation are partnering to develop an antiviral nasal spray to prevent and reduce incidence and severity of respiratory viral infections in people with chronic lung diseases like COPD.
Read More
Intranasal Corticosteroids May Help Improve Outcomes in Severe COVID-19
Patients who regularly use intranasal corticosteroids were less likely to develop severe COVID-19-related disease, including a 20 to 25% lower risk of hospitalization, ICU admission and mortality.
Read More
FDA Approves Bayer’s Over the Counter Nasal Allergy Spray
The FDA removed the prescription requirement for Bayer’s Asteprofor seasonal and year-round allergic rhinitis nasal spray.
Read More
Nasal Spray Drug Delivery for Parkinson’s Disease
Scientists at the University of York have made progress in the development of a nasal spray...
Read More
Could A Nasal Spray Prevent Coronavirus Transmission?
A new nasal antiviral blocked transmission of SARS-CoV-2 in a study of ferrets, suggesting it may prevent infection in people.
Read More
Could a Nasal Spray Prevent Coronavirus Transmission?
A nasal antiviral created by Columbia University researchers blocked transmission of SARS-CoV-2 in ferrets.
Read More
Intranasal Medication Delivery Becoming More Popular in EDs
Administering medications through the nose as an alternative to injections or IVs is becoming increasingly popular in emergency departments and ambulances.
Read More
FDA Rejects Intranasal Naloxone
The US FDA has rejected an application from Amphastar Pharmaceuticals Inc to market an intranasal version of the emergency opioid-overdose treatment, naloxone.
Read MoreNasal Spray May Replace Pills In Delivering Drugs To The Brain
In an effort to find more efficient ways of delivering drugs to the brain, Danish researchers tested a natural sugar polymer that is capable of carrying drugs through the nasal wall and into the brain.
Read MoreNasacort Allergy 24HR Nasal Spray Available OTC in US
Nasacort Allergy 24HR Nasal Spray is now available over-the-counter in the United States. The medication is designed to relieve the full range of seasonal and year-round nasal allergy symptoms, including nasal congestion, in adults and children 2 years of age and older.
Read More